Next Article in Journal
Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report
Next Article in Special Issue
PRPS-Associated Disorders and the Drosophila Model of Arts Syndrome
Previous Article in Journal
Effects of Apigenin on RBL-2H3, RAW264.7, and HaCaT Cells: Anti-Allergic, Anti-Inflammatory, and Skin-Protective Activities
Previous Article in Special Issue
Abnormal Social Interactions in a Drosophila Mutant of an Autism Candidate Gene: Neuroligin 3
Open AccessReview

Pharmacological Treatment of Alzheimer’s Disease: Insights from Drosophila melanogaster

by Xingyi Cheng 1,2,†, Chaochun Song 1,2,†, Yanjiao Du 1,2, Uma Gaur 1,2 and Mingyao Yang 1,2,*
Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu 611130, China
Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(13), 4621;
Received: 19 May 2020 / Revised: 22 June 2020 / Accepted: 25 June 2020 / Published: 29 June 2020
(This article belongs to the Special Issue Role of Drosophila in Human Disease Research)
Aging is an ineluctable law of life. During the process of aging, the occurrence of neurodegenerative disorders is prevalent in the elderly population and the predominant type of dementia is Alzheimer’s disease (AD). The clinical symptoms of AD include progressive memory loss and impairment of cognitive functions that interfere with daily life activities. The predominant neuropathological features in AD are extracellular β-amyloid (Aβ) plaque deposition and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Because of its complex pathobiology, some tangible treatment can only ameliorate the symptoms, but not prevent the disease altogether. Numerous drugs during pre-clinical or clinical studies have shown no positive effect on the disease outcome. Therefore, understanding the basic pathophysiological mechanism of AD is imperative for the rational design of drugs that can be used to prevent this disease. Drosophila melanogaster has emerged as a highly efficient model system to explore the pathogenesis and treatment of AD. In this review we have summarized recent advancements in the pharmacological research on AD using Drosophila as a model species, discussed feasible treatment strategies and provided further reference for the mechanistic study and treatment of age-related AD. View Full-Text
Keywords: Alzheimer’s disease; AD model; pharmacology; signaling pathways; Drosophila Alzheimer’s disease; AD model; pharmacology; signaling pathways; Drosophila
Show Figures

Figure 1

MDPI and ACS Style

Cheng, X.; Song, C.; Du, Y.; Gaur, U.; Yang, M. Pharmacological Treatment of Alzheimer’s Disease: Insights from Drosophila melanogaster. Int. J. Mol. Sci. 2020, 21, 4621.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop